TY - JOUR
T1 - Urinary excretion of angiotensin I, II, arginine vasopressin and oxytocin in patients with anaphylactoid reactions
AU - Hermann, K.
AU - Rittweger, R.
AU - Ring, J.
N1 - Funding Information:
This research was supported by the SFB 200/C8 and a grant from the DFG (He 1128/2 - 4). We are grateful to M. Groenenwald and G. Heske for technical assistance in the experiments and in preparation of the manuscript.
PY - 1992
Y1 - 1992
N2 - Human urine samples, purified on octadecasilyl-silica cartridges, contained immunoreactive angiotensin I, II, arginine vasopressin and oxytocin. The daily excretion of these peptides in healthy volunteers was 190.00 ± 38.43 (n = 12), 17.48 ± 3.09 (n = 12), 63.43 ± 14.84 (n = 8) and 13.52 ± 1.42 (n = 7) pmol/24 hr, respectively (mean ± s.e.m.). Patients with a history of anaphylactoid reactions to drugs or food additives showed clinical symptoms such as urticaria, flush, nausea, dizziness and hypotension after oral provocation with cyanocobalamine, propyphenazone, acetylsalicylic acid and sodium benzoate. In five of the seven patients, angiotensin I and II were increased several fold in the urine fractions after symptoms were reported. The average increase in the urine concentration of both peptides was fourfold and 5.5-fold. In three out of five patients, the mean excretion of arginine vasopressin and oxytocin immunoreactive material was also elevated by a factor of 5.7 and 4.4, respectively. Oral provocation with a placebo failed to elicit anaphylactoid symptoms or an increase in the urine levels of angiotensin I or angiotensin II. Angiotensin I and angiotensin II-like immunoreactivity could be characterized on HPLC as Ile5-angiotensin I, Ile5-angiotensin II and angiotensin II metabolites. HPLC characterization of immunoreactive arginine vasopressin and oxytocin in two different gradient systems showed retention times different than the retention times of the corresponding synthetic standard peptides indicating that both peptides are not authentic AVP and OXT. These results suggest that angiotensin I and angiotensin II may be involved in the clinical events observed during some forms of anaphylactoid reactions.
AB - Human urine samples, purified on octadecasilyl-silica cartridges, contained immunoreactive angiotensin I, II, arginine vasopressin and oxytocin. The daily excretion of these peptides in healthy volunteers was 190.00 ± 38.43 (n = 12), 17.48 ± 3.09 (n = 12), 63.43 ± 14.84 (n = 8) and 13.52 ± 1.42 (n = 7) pmol/24 hr, respectively (mean ± s.e.m.). Patients with a history of anaphylactoid reactions to drugs or food additives showed clinical symptoms such as urticaria, flush, nausea, dizziness and hypotension after oral provocation with cyanocobalamine, propyphenazone, acetylsalicylic acid and sodium benzoate. In five of the seven patients, angiotensin I and II were increased several fold in the urine fractions after symptoms were reported. The average increase in the urine concentration of both peptides was fourfold and 5.5-fold. In three out of five patients, the mean excretion of arginine vasopressin and oxytocin immunoreactive material was also elevated by a factor of 5.7 and 4.4, respectively. Oral provocation with a placebo failed to elicit anaphylactoid symptoms or an increase in the urine levels of angiotensin I or angiotensin II. Angiotensin I and angiotensin II-like immunoreactivity could be characterized on HPLC as Ile5-angiotensin I, Ile5-angiotensin II and angiotensin II metabolites. HPLC characterization of immunoreactive arginine vasopressin and oxytocin in two different gradient systems showed retention times different than the retention times of the corresponding synthetic standard peptides indicating that both peptides are not authentic AVP and OXT. These results suggest that angiotensin I and angiotensin II may be involved in the clinical events observed during some forms of anaphylactoid reactions.
UR - http://www.scopus.com/inward/record.url?scp=0026660599&partnerID=8YFLogxK
U2 - 10.1111/j.1365-2222.1992.tb02830.x
DO - 10.1111/j.1365-2222.1992.tb02830.x
M3 - Article
C2 - 1422942
AN - SCOPUS:0026660599
SN - 0954-7894
VL - 22
SP - 845
EP - 853
JO - Clinical and Experimental Allergy
JF - Clinical and Experimental Allergy
IS - 9
ER -